Salta alla navigazione principale Salta alla ricerca Salta al contenuto principale

A phase I study of autologous mesenchymal stromal cells for severe steroid-dependent nephrotic syndrome

  • M. Vivarelli*
  • , M. Colucci
  • , M. Algeri
  • , F. Zotta
  • , F. Emma
  • , I. L'Erario
  • , M. Busutti
  • , S. Rota
  • , C. Capelli
  • , M. Introna
  • , M. Todeschini
  • , F. Casiraghi
  • , A. Perna
  • , T. Peracchi
  • , Salvo A. De
  • , N. Rubis
  • , Franco Locatelli
  • , G. Remuzzi
  • , P. Ruggenenti
  • *Autore corrispondente per questo lavoro
  • IRCCS Ospedale pediatrico Bambino Gesù - Roma
  • Azienda Socio Sanitaria Territoriale (ASST)
  • ASST Papa Giovanni XXIII
  • IRCCS Istituto di ricerche farmacologiche Mario Negri - Milano, Bergamo, Ranica

Risultato della ricerca: Contributo in rivista › Articolo

Abstract

BACKGROUNDSevere forms of idiopathic nephrotic syndrome (INS) require prolonged immunosuppressive therapies and repeated courses of high-dose glucocorticoids. Mesenchymal stromal cells (MSCs) have promising immunomodulatory properties that may be employed therapeutically to reduce patient exposure to medications and their side effects.METHODSWe performed a phase I open-label trial assessing safety and feasibility of autologous bone marrow-derived MSCs (BM-MSCs) in children and young adults with severe forms of steroid-dependent nephrotic syndrome. Following autologous BM-MSC preparation and infusion, oral immunosuppression was tapered. Safety, efficacy, and immunomodulatory effects in vivo were monitored for 12 months.RESULTSSixteen patients (10 children, 6 adults) were treated. Adverse events were limited and not related to BM-MSC infusions. All patients relapsed during follow-up, but in the 10 treated children, time to first relapse was delayed (P = 0.02) and number of relapses was reduced (P = 0.002) after BM-MSC infusion, compared with the previous 12 months. Cumulative prednisone dose was also reduced at 12 months compared with baseline (P < 0.05). No treatment benefit was observed in adults.In children, despite tapering of immunosuppression, clinical benefit was mirrored by a significant reduction in total CD19+, mature, and memory B cells and an increase in regulatory T cells in vivo up to 3-6 months following BM-MSC infusionCONCLUSIONTreatment with autologous BM-MSCs is feasible and safely reduces relapses and immunosuppression at 12 months in children with severe steroid-dependent INS. Immunomodulatory studies suggest that repeating MSC infusions at 3-6 months may sustain benefit.TRIAL REGISTRATIONEudraCT 2016-004804-77.FUNDINGAIFA Ricerca Indipendente 2016-02364623.
Lingua originaleInglese
pagine (da-a)1-13
Numero di pagine13
RivistaJCI insight
Volume8
Numero di pubblicazione18
DOI
Stato di pubblicazionePubblicato - 2023

All Science Journal Classification (ASJC) codes

  • Medicina Generale

Keywords

  • Clinical Trials
  • Immunotherapy
  • Nephrology

Fingerprint

Entra nei temi di ricerca di 'A phase I study of autologous mesenchymal stromal cells for severe steroid-dependent nephrotic syndrome'. Insieme formano una fingerprint unica.

Cita questo